(Q39611506)

English

Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study

scientific article published on April 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study (English)

1 reference

Europe PubMed Central

13 September 2017

0 references

Human T-lymphotropic virus 1

0 references

1 reference

based on heuristic

inferred from title

spastic paraparesis

1 reference

based on heuristic

inferred from title

author name string

Yamasaki K

1

1 reference

Europe PubMed Central

13 September 2017

Kira J

2

1 reference

Europe PubMed Central

13 September 2017

Koyanagi Y

3

1 reference

Europe PubMed Central

13 September 2017

Kawano Y

4

1 reference

Europe PubMed Central

13 September 2017

Miyano-Kurosaki N

5

1 reference

Europe PubMed Central

13 September 2017

Nakamura M

6

1 reference

Europe PubMed Central

13 September 2017

Baba E

7

1 reference

Europe PubMed Central

13 September 2017

Suzuki J

8

1 reference

Europe PubMed Central

13 September 2017

Yamamoto A

9

1 reference

Europe PubMed Central

13 September 2017

Yamamoto N

10

1 reference

Europe PubMed Central

13 September 2017

Kobayashi T

11

1 reference

Europe PubMed Central

13 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 1997

1 reference

Europe PubMed Central

13 September 2017

Journal of the Neurological Sciences

1 reference

Europe PubMed Central

13 September 2017

147

1 reference

Europe PubMed Central

13 September 2017

135-144

1 reference

Europe PubMed Central

13 September 2017

2

1 reference

Europe PubMed Central

13 September 2017

Human T-cell leukaemia virus type I and neurological disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

HTLV-I-associated myelopathy in a Californian: diagnosis by reactivity to a viral recombinant antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Anti-viral and immunomodulatory effects of interferon-alpha on cultured lymphocytes from patients with human T lymphotropic virus type I-associated myelopathy (HAM/TSP).

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Increases in helper inducer T cells and activated T cells in HTLV-I-associated myelopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Antibody titers to HTLV-I-p40tax protein and gag-env hybrid protein in HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with increased HTLV-I proviral DNA load

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

In vivo infection of human T-cell leukemia virus type I in non-T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

HTLV-I-associated myelopathy endemic in Texas-born residents and isolation of virus from CSF cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Suppressive effects of interferons on the production and release of human T-lymphotropic virus type-I (HTLV-I).

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Retrovirus-associated myelopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

The effect of intraventricular interferon on subacute sclerosing panencephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2896%2905319-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0022-510X(96)05319-1

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39611506&oldid=1845409200"